Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02542202 · ClinicalTrials.gov registry record · NA
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
A NA study, sponsored by University of Chicago.
- Terminated
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT02542202 is a NA study that was terminated before completion, run by University of Chicago. The registered enrollment target is 25 participants.
The verdict
NCT02542202, a NA study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with kidney cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
Interventions
- RADIATION Stereotactic Body Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2023-03-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02542202
The ClinicalTrials.gov registry entry for NCT02542202 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stereotactic Body Radiation Therapy is the first listed.
NCT02542202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02542202 about?
NCT02542202 is a clinical study titled "Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer". This pilot clinical trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with kidney cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Stereotactic radiosurgery, also known as stereotactic body radiation ...
What is the current status of trial NCT02542202?
This trial is currently terminated. It is a NA study. The enrollment target is 25 participants. The study started on 2015-05-01. Estimated completion is 2023-03-23.
What interventions are being tested in trial NCT02542202?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02542202?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.